Biotechnology meetings & conferences

International Society for Disease Surveillance Annual Conference

The ISDS Annual Conference is the premier event dedicated to the advancement of the science and practice of biosurveillance. This year’s theme, Expanding Collaborations to Chart a New Course in Public Health Surveillance, will highlight the importance of working together across agencies, sectors, and disciplines to improve surveillance methods and population health outcomes. The conference will be held at the Sheraton San Diego Hotel and Marina in San Diego, CA, December 4-5, 2012, with Pre-Conference Workshops on December 3rd.

The ISDS Conference draws professionals from a broad range of disciplines— epidemiology and computer science to mathematical modeling and health policy—to learn and contribute the latest achievements, methodologies, best practices, conceptual frameworks, and technical innovations in the rapidly evolving field of biosurveillance. This year's conference will provide fertile ground for cultivating new ideas and partnerships with roundtable discussions, panels and other opportunities to collaborate.

The scope of this conference includes all of the components, policies, methods, practices, infrastructure, research and evaluation related to timely surveillance of communicable diseases, chronic diseases and injuries. This includes notifiable conditions, adverse events and emerging/novel threats; biological, chemical, and radiological health threats; plant, animal, and food surveillance; and environmental monitoring.

Molecular Pharming - Recent Progress in Manufacturing Medicines in Plants

Friday, 21 September 2012 09:00 - 17:00 London, United Kingdom

Molecular Pharming is on the brink of taking off! After two decades of development and academic proofs of principle, a number of recent advances have moved the technology rapidly towards commercialisation. The first products are now being licensed in the USA. The first-in-human clinical trial of a plant derived monoclonal antibody has been performed in Europe. And there has been significant investment into manufacturing facilities around the world.

This meeting will review the progress of the field, highlight major technological advances and scan the horizon for future developments.

Contact Details

Email: enquiries@euroscicon.com

Web: www.euroscicon.com

For all accommodation and travel enquiries please contact accommodationandtravel@euroscicon.com

3rd Annual International Conference on Advances in Biotechnology (BioTech 2013)

18 - 19 March 2013 Singapore

Biotechnology is a field of applied biology that involves the use of living organisms and bioprocesses in engineering, technology, medicine and other fields requiring bioproducts. The concept encompasses a wide range of procedures for modifying living organisms according to human purposes - going back to domestication of animals, cultivation of plants, and "improvements" to these through breeding programs that employ artificial selection and hybridization.

This multi-disciplinary conference aims to provide a challenging forum and vibrant opportunity for researchers and industry practitioners to share their original research results and practical development experiences on specific new challenges and emerging issues.

Topics of interest include, but are not limited to:

Pharmaceutical / Medicine

• Structural Biology
• Proteomics
• Cell Cycle and Oncology
• Medical Microbiology
• Diagnostic Pathology
• Clinical Chemistry
• Haematology
• Diagnostic Imaging
• Medical Imaging and Methods
• Sonography
• Molecular and Cell Biology
• Biochemistry
• Immunology
• Genetics
• Neurobiology
• Drug production
• Pharmacogenomics
• Gene therapy
• Factors for transcribing DNA into RNA
• Monoclonol antibodies
• Pathogenesis of Human Diseases
• Presymptomatic testing

Food and Agriculture

• Genetic engineering
• Genomics
• Tissue culture
• Cell fusion
• Molecular biology
• Enzymology
• Fermentation processes
• Instrumentation and diagnostic methods
• Food processing
• Biofertilizer
• Waste Technology
• Environment Control
• Pest and diseases resistant crop
• High value addictives and chemical products
• Immunological techniques
• Signal transduction
• Conjugation
• Classical mutagenesis
• Conjugation process
• Hybridisation

CONFERENCE SECRETARIAT

Global Science & Technology Forum (GSTF)
10 Anson Road, International Plaza,
Singapore 079903
DID : +65 6327 0166
Fax : +65 6327 0162

For Conference Information info@advbiotech.org
For Registration, Accommodation or Visa Assistance secretariat@advbiotech.org

Bioplasma World Asia 2012

July 18-19, 2012 Hong Kong

Bioplasma World Asia 2012 provides Asia’s ONLY Bioplasma and blood products focused conference that brings together regional and international fractionators, regulators and technology specialists to discuss strategies and best practices.

Bioplasma World Asia 2012 brings to you:

-The most targeted platform to meet Asian and international plasma fractionators

-Case studies and discussions from senior level decision makers who will influence the direction of fractionation industry

-Both strategic and technological developments in the fractionation industry.

Asia’s plasma products market update

Asia’s regulatory and quality trends and challenges

-Manufacturing and operational excellence.

-Pathogenic quality control

-Clinical developments and applications

-Innovation and advances in plasma processing

-New product show case

IMAPAC PTE. LTD.

298 Tiong Bahru Road,
#20-04 Central Plaza,
Singapore 168730

Tel: +65 6493 2093
Fax: +65 6270 2792

Email: info@imapac.com

IEEE-EMBS Micro- and Nanoengineering in Medicine Conference (MNMC 2012)

Translating Technology from the Bench to the Bedside

December 3-7, 2012 The Westin Maui Resort and Spa, Ka’anapali, Hawaii

Various biomedical grand challenges facing our society and the world can be addressed by interfacing biology and medicine with micro- and nanoscale technologies. These technologies hold great potential to impact early diagnosis, therapeutics, and management of disease. IEEE EMBS is sponsoring the first Conference on Micro- and Nanoengineering in Medicine to foster interaction between scientists, engineers and medical researchers in the context of real-world medical needs and issues. The Conference will promote vigorous and open dialogue towards the development of cutting edge technologies for faster, more quantitative, and less expensive biomedical solutions using advances in micro and nanotechnology.

3rd Annual Modern Challenges in Therapeutic Protein Production Event

Thursday, 14 June 2012 London, United Kingdom 

The purpose of this annual event is to look at the challenges facing therapeutic protein production and demystify some of the novel approaches and new technologies currently being developed.

Contact Details
Email: enquiries@euroscicon.com

Web: www.lifescienceevents.com

For all accommodation and travel enquiries please contact accommodationandtravel@euroscicon.com

39th Annual Meeting & Exposition of the Controlled Release Society

Smart Materials - From Innovation to Translation
July 15-18, 2012
Centre des Congrès de Québec
Québec City, Canada

Join the Controlled Release Society as it meets in beautiful Québec City, Canada next July. The 2012 scientific program of the Controlled Release Society promises an exciting line-up of world-class scientists representing the continuum of materials science and engineering, the cellular and biological response to materials, the response of various formulations to materials, and the translational considerations, with a common focus on the controlled delivery of active agents.

Session Topics

Bioactive Materials: Biomaterials

Bioactive Materials: DNA and RNAi Delivery

Bioactive Materials: Drug Delivery to the Brain

Bioactive Materials: Inorganic Nanosystems

Bioactive Materials: Intracellular Processes

Bioactive Materials: Nanomedicines

Bioactive Materials: Oncology and Tumor Targeting

Bioactive Materials: Oral Controlled Release

Bioactive Materials: Stem Cell and Regenerative Medicines

Bioactive Materials: Theranostics and Cancer Nanotechnologies

Bioactive Materials: Transdermal Drug Delivery

Bioactive Materials: Translational Nanomedicine

Bioactive Materials/C&DP: Imaging Diagnostics for Material Characterization

Bioactive Materials/C&DP: Nanofibers

Bioactive Materials/Veterinary: Protein and Vaccine Delivery

C&DP: Consumer and Industrial Applications of Nanoparticle Technology

C&DP: Fragrances and Flavors

C&DP: Hydrogel Delivery Systems in Consumer Products

C&DP: Nutraceuticals and Functional Foods

Veterinary: Protein and Peptide Therapeutics for Animal Patients

The Controlled Release Society
3340 Pilot Knob Road
St. Paul, MN U.S.A. 55121

Phone: +1.651.454.7250
Facsimile: +1.651.454.0766
E-mail: crs@scisoc.org

18th Annual International Society for Cellular Therapy Meeting

June 5-8, 2012 Seattle, Washington

ISCT is pleased to invite you to attend the 18th Annual Meeting in Seattle, Washington, USA. Over 700 International delegates are expected to be in attendance. Attendees include:

MD and/or PhD clinicians and scientists
Laboratory professionals involved in cell-processing programs/facilities
Industry personnel from cell therapy or enabling technology companies
Regulatory professionals

12th International Symposium on Biosafety of Genetically Modified Organisms (ISBGMO12)

17-20 September 2012 St Louis, Missouri

The ISBGMO is a unique opportunity for scientists from across the globe to share experiences and engage in open and meaningful dialogue about biosafety.

Participants include scientists involved in biosafety research and policy, including regulatory authorities, technology developers, academics, non-government organizations, and other credible stakeholders.

The discussion at this ISBGMO12 will be focused on a theme: CONSIDERING BIOSAFETY IN THE APPLICATION OF BIOTECHNOLOGY TO MEET THE CHANGING NEEDS OF AGRICULTURE, HEALTH, AND THE ENVIRONMENT.

Under this theme, presentations and posters in the sessions, mini-symposia, and workshops will potentially address such timely topics, as they relate to biosafety:

New approaches in genetic engineering
Genetically engineered animals/insects
Biotechnology and climate change
Biotechnology and biofuels/energy
Biotechnology for developing countries
Transferring data for risk assessment across environments
Genetically engineered crops and agricultural sustainability
Post-market monitoring
Defining protection goals for risk assessment
Defining the receiving environment
Understanding environmental fate
Key discussions under the Cartagena Protocol on Biosafety
Effective capacity building for biotechnology regulation
And others...

The ISBGMO is a bienniel international meeting organized by the International Society for Biosafety Research (ISBR), a society whose membership is composed of individuals with an interest in risk assessment and research related to the environmental risks associated with genetically modified organisms (http://www.isbr.info/).

The ISBGMOs have been offered on a biennial basis since 1990, at various locations throughout the world, including most recently in Argentina (2010), New Zealand (2008), South Korea (2006), France (2004), China(2002), Canada (2000). The 2012 symposium in St. Louis will be the first time it has been offered in the US since it was held in Monterey, CA in 1994.

The Donald Danforth Plant Science Center in St. Louis, whose mission and goals are closely tied to the theme of ISBGMO12, is the local host for this symposium.

For queries please contact: Customer Services Officer
Email: Customerservice-ISBGMO12@elsevier.com

2012 BIO International Convention

June 18-21, 2012 Boston, Massachusetts

Session Track Descriptions
1. Achieving Regulatory Approval and Compliance: Regulatory and legal developments at the Food and Drug Administration (FDA) and across the globe that will affect biotech companies’ ability to research and develop the healthcare products, successfully bring these products to market, and maintain approval and compliance. Session length: 75 to 90 minutes

2. Biofuels & Biobased Chemicals: Breakthrough industrial biotechnologies for biofuels, renewable chemicals, and biobased products making manufacturing processes cleaner and more efficient, creating new materials, food ingredients and other products, unlocking cleaner and greener sources of energy, and reducing industrial waste. Session length: 75 to 90 minutes

3. Biotech Patenting and Tech Transfer: Latest trends in intellectual property protection for biotech innovations, and pragmatic approaches to challenges and opportunities in global biotech licensing, tech transfer, and collaborations. Session length: 75 to 90 minutes

4. Business Development: Analysis of the latest biotech partnering and alliance deal trends. Session length: 75 to 90 minutes

5. Drug Discovery & Development: Discovery research, preclinical safety assessment, clinical trials, and more. Session length: 75 to 90 minutes

6. Finance: Analysis of the latest biotech financing, investment and deal trends. Session length: 75 to 90 minutes

7. Food & Agriculture: Moving Beyond the Debate: Effectively Addressing Global Regulatory and Acceptance Issues to Realize Agricultural Biotechnology’s Full Potential. Topics could include: emerging markets and grain trade issues; U.S. regulations and impediments to international competitiveness; new genetic modification technologies: science, applications and issues; Ag biotech’s role in strengthening rural economies, job creation, and trade; working with like-minded countries to establish trade and regulatory cooperation; coexistence; agricultural research/extension programs/land grant universities; GE animal regulatory issues – domestic and international; challenges and opportunities of emerging biotechnology companies; stewardship – the movement of a biotechnology product from the lab to the end of the supply chain; agricultural energy – examining federal programs, partnerships and policies, and the future of biotechnology to U.S. and global energy security; the Coordinated Framework after 25 years; and effectively addressing consumer attitudes and acceptance. Session length: 75 to 90 minutes

8. Global Innovations & Markets: In-depth analysis of biotechnology market opportunities and innovation systems, especially in emerging economies. Session length: 75 to 90 minutes

9. Health Policy & Reimbursement: Emerging health policy issues and key developments impacting the market and reimbursement landscape for innovative biopharmaceutical therapies. BIO is seeking submissions related to policy developments related to accountable care organizations; Patient-Centered Outcomes Research Institute (PCORI) and comparative effectiveness research; health insurance exchanges, the essential benefits package, and the impact on drug formularies; the shifting role of Medicaid and impact on biopharmaceuticals; investor perspectives on reimbursement; and federal budget cuts, the IPAB and the impact on biopharmaceuticals. Session length: 75 to 90 minutes

10. Innovations in Vaccines: Exciting updates on the newest developments in vaccines for prevention and treatment from infectious diseases to cancer. Topics could include: the impact of healthcare reform on vaccines business opportunity; international opportunities for vaccine group; therapeutic vaccines; influenza vaccines; and emerging infections –dengue, hospital-acquired infections, etc. Session length: 75 to 90 minutes

11. International Case Studies: 45-minute sessions where countries and regions around the world will present specific initiatives to generate promising new discoveries, create jobs, and spur economic growth and development. Challenges as well as successful examples on what it takes to create local, national, and/or regional value in this highly innovative technology sector will be discussed. Individuals with Exhibit Booth Personnel registrations are allowed to attend this track. (Note: Priority as session organizer is given to International Delegation and Pavilion Organizers. Submissions from clusters and individual companies will not be considered for this track. BIO will be accepting submissions online from October 3 -October 28, 2011).Session length: 45 minutes

12. Manufacturing of Biologics & Drugs: Recent developments in biologics and drug manufacturing, including quality-by-design, process analytical technology, compliance activities, and supply chain management. Session length: 75 to 90 minutes

13. Personalized Medicine & Diagnostics: From R&D, through regulatory oversight, to reimbursement and patient access: the development of novel diagnostic technologies and the related therapeutics that they target in the evolving healthcare system. Session length: 75 to 90 minutes

Contact Us
Program Inquiries
program@bio.org

Exhibiting or Advertising
exhibit@bio.org

General Questions
reg2012@bio.org

Housing
BIO@tphousing.com